🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

28 recruiting trials

for Neovascular Age-related Macular Degeneration(nAMD)

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration NCT07630649Phase 212 sites📍 Phoenix📍 Bakersfield📍 Fullerton Adverum Biotechnologies, Inc. · Tests: Ixo-vec Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) NCT06141460Phase 1, Phase 21 site📍 Tianjin Shanghai Refreshgene Technology Co., Ltd. · Tests: RRG001 A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD) NCT07547228Phase 1, Phase 21 site📍 Singapore Intra-IMMUSG Pte Ltd · Tests: PRL3-ZUMAB, Normal Saline (0.9% Sodium Chloride) Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) NCT05672121Phase 1, Phase 21 site📍 Beijing Chengdu Origen Biotechnology Co., Ltd. · Tests: KH631 Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting NCT07249216NA1 site📍 Singapore Singapore National Eye Centre · Tests: Faricimab, Ranibizumab Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD) NCT05803785Phase 12 sites📍 Sydney📍 Sydney Benobio Co., Ltd. · Tests: BBC1501 Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study NCT07516132Phase 38 sites📍 Bakersfield📍 Santa Barbara📍 Waterford Ocular Therapeutix, Inc. · Tests: OTX-TKI Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) NCT07482176Phase 379 sites📍 Mesa📍 Phoenix📍 Phoenix Adverum Biotechnologies, Inc. · Tests: Ixo-vec, Aflibercept A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD NCT06346600n/a10 sites📍 Boston📍 Katy📍 Norfolk Skyline Therapeutics · Tests: SKG0106 A Study to Compare GNR-139 and Eylea® in Patients With nAMD NCT07844148Phase 314 sites📍 Cheboksary📍 Chelyabinsk📍 Yekaterinburg AO GENERIUM · Tests: aflibercept, Eylea A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration NCT07614776Phase 381 sites📍 Fullerton📍 Long Beach📍 Modesto Amgen · Tests: ABP 938 8 mg, Aflibercept (US) 8 mg CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I) NCT06031727EARLY Phase 12 sites📍 Shanghai📍 Tianjin HuidaGene Therapeutics Co., Ltd. · Tests: HG202 A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD NCT06847542Phase 361 sites📍 Innsbruck📍 Linz📍 Mistelbach Hoffmann-La Roche · Tests: Susvimo PDS Implant, Ranibizumab DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information. NCT07308639n/a1 site📍 Leverkusen Bayer · Tests: anti-VEGF medication Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration NCT07064759Phase 3126 sites📍 Scottsdale📍 Sun City📍 Tucson 4D Molecular Therapeutics · Tests: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients NCT07053358EARLY Phase 11 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: LX111 Injection Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) NCT06458595Phase 1, Phase 21 site📍 Tianjin Chengdu Origen Biotechnology Co., Ltd. · Tests: KH658 Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) NCT07007065Phase 3137 sites📍 Mesa📍 Sun City📍 Campbell AbbVie · Tests: Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control Gene Therapy(FT-003) for Wet AMD NCT06492863Phase 1, Phase 21 site📍 Tianjin Frontera Therapeutics · Tests: FT-003 Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD NCT06672536Phase 1, Phase 21 site📍 Tianjing Sinocelltech Ltd. · Tests: SCT520FF, SCT520FF, SCT520FF, EYLEA 2 MG Regulatory Post-Marketing Surveillance Study for Brolucizumab NCT04985487n/a28 sites📍 Daegu📍 Goyang-si📍 Guri-si Novartis Pharmaceuticals · Tests: brolucizumab A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD NCT07275840Phase 21 site📍 Shanghai Innovent Biologics Technology Limited (Shanghai R&D Center) · Tests: IBI302 8mg dose Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) NCT07317934Phase 336 sites📍 Hefei📍 Beijing📍 Beijing Innostellar Biotherapeutics Co.,Ltd · Tests: LX102, Aflibercept Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration NCT07776522Phase 216 sites📍 Beijing📍 Beijing📍 Jilin City West China Hospital · Tests: JWK001, Aflibercept (2.0 mg) A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) NCT04853251Phase 452 sites📍 Mesa📍 Bakersfield📍 Huntington Beach Genentech, Inc. · Tests: PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection) Real-world Study of Aflibercept 8 mg in nAMD NCT07640997n/a27 sites📍 Beijing📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Aflibercept 8mg Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) NCT05986864Phase 1, Phase 29 sites📍 St. Petersburg📍 Boston📍 Katy Skyline Therapeutics (US) Inc. · Tests: SKG0106 Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting NCT05093374Phase 41 site📍 Vienna Medical University of Vienna · Tests: anti-VEGF agent, anti-VEGF agent
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy